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Background. We have previously described a four antigen malaria vaccine consisting of DNA plasmids boosted by
recombinant poxviruses which protects a high percentage of rhesus monkeys against Plasmodium knowlesi (Pk) malaria. This
is a multi-stage vaccine that includes two pre-erythrocytic antigens, PkCSP and PkSSP2(TRAP), and two erythrocytic antigens,
PkAMA-1 and PkMSP-1(42kD). The present study reports three further experiments where we investigate the effects of DNA
dose, timing, and formulation. We also compare vaccines utilizing only the pre-erythrocytic antigens with the four antigen
vaccine. Methodology. In three experiments, rhesus monkeys were immunized with malaria vaccines using DNA plasmid
injections followed by boosting with poxvirus vaccine. A variety of parameters were tested, including formulation of DNA on
poly-lactic co-glycolide (PLG) particles, varying the number of DNA injections and the amount of DNA, varying the interval
between the last DNA injection to the poxvirus boost from 7 to 21 weeks, and using vaccines with from one to four malaria
antigens. Monkeys were challenged with Pk sporozoites given iv 2 to 4 weeks after the poxvirus injection, and parasitemia was
measured by daily Giemsa stained blood films. Immune responses in venous blood samples taken after each vaccine injection
were measured by ELIspot production of interferon-c, and by ELISA. Conclusions. 1) the number of DNA injections, the
formulation of the DNA plasmids, and the interval between the last DNA injection and the poxvirus injection are critical to
vaccine efficacy. However, the total dose used for DNA priming is not as important; 2) the blood stage antigens PkAMA-1 and
PkMSP-1 were able to protect against high parasitemias as part of a genetic vaccine where antigen folding is not well defined;
3) immunization with PkSSP2 DNA inhibited immune responses to PkCSP DNA even when vaccinations were given into
separate legs; and 4) in a counter-intuitive result, higher interferon-c ELIspot responses to the PkCSP antigen correlated with
earlier appearance of parasites in the blood, despite the fact that PkCSP vaccines had a protective effect.
Citation: Weiss WR, Kumar A, Jiang G, Williams J, Bostick A, et al (2007) Protection of Rhesus Monkeys by a DNA Prime/Poxvirus Boost Malaria Vaccine
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INTRODUCTION
In recent years, research on vaccines against malaria infection has
been moving along two parallel tracks. On the one track are the
recombinant protein vaccines given with novel adjutants. Human
phase 1 and 2a/b trials of several of these vaccines have shown
moderate levels of efficacy [1–10]. Great emphasis is placed on the
proper folding and glycosylation of recombinant protein vaccines,
particularlyofthe bloodstage antigens,asprotective antibodiesoften
recognize conformational epitopes on these antigens. [11–23].
The other track of malaria vaccine development is genetic
vaccination with DNA plasmids, recombinant viral vectors, or often
with both in a DNA prime-viral boost combination. In rodent
models, genetic vaccines produce strong T cell responses of both
CD4
+ and CD8
+ subsets, as well as specific antibodies. The murine
prime-boost vaccines have been very successful at attacking the
malaria parasite as itdevelopsinsidethehepatocyte prior to infecting
red blood cells [24–31]. Genetic pre-erythrocytic vaccines have also
begun to be tested in human phase 1 and 2a malaria trials [32–44].
However, these initial studies show that genetic vaccines are less
immunogenic in humans, with only slight efficacy in preventing
parasitemia following experimental sporozoite infection.
Several years ago, we decided to develop a primate malaria
vaccine model for sporozoite infection. This would allow us to
study immunity against sporozoites, liver stage, and blood stage
malaria in a model system closer to the human than the mouse,
and to optimize the delivery of genetic malaria vaccines as a guide
to planning human trials. We chose to use Plasmodium knowlesi (Pk)
in the Indian rhesus monkey, as sporozoites are highly infectious
and blood stage parasitemias rise to high levels similar to P.
falciparum in humans. Our previous studies have shown that DNA
prime-viral boost malaria vaccines can partially protect monkeys
[45,46]. Our vaccine regimen uses a mix of four Pk antigens
(PkCSP, PkSSP2 (TRAP), PkAMA1, and PkMSP1-42kD subunit).
The vaccine has typically used three injections of DNA in PBS for
priming, followed by a recombinant COPAK poxvirus boost after
a 16 week interval. This vaccine has protected approximately 60%
of Indian origin rhesus monkeys against potentially lethal Pk
malaria (10% sterile protection plus an additional 50% which have
parasites in their blood but self-cure). In this paper, we will refer to
Academic Editor: Derya Unutmaz, New York University School of Medicine,
United States of America
Received July 20, 2007; Accepted September 11, 2007; Published October 24,
2007
This is an open-access article distributed under the terms of the Creative
Commons Public Domain declaration which stipulates that, once placed in the
public domain, this work may be freely reproduced, distributed, transmitted,
modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by DOD funds allocated to the Naval Medical
Research Center (work unit number 6000.RAD1.F.A0309).
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: weissw@nmrc.navy.
mil
PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1063this vaccine as DNA Pk463/COPAK, to emphasize that it uses
four Pk antigens and has three doses of DNA before the
recombinant COPAK poxvirus boost.
The three experiments presented in this paper all include the
DNA Pk463/COPAK vaccine, and compare variations on the
priming regimen or the number of antigens included. We hoped
that some of the variations, such as the use of high doses of DNA
plasmid or the use of DNA on poly-lactic co-glycolide (PLG)
particles [47–50], might lead to better protection. Other varia-
tions, such as shortening vaccination intervals or priming with
single DNA doses, were aimed at streamlining vaccine schedules.
By comparing the four antigen vaccine with vaccines containing
only the pre-erythrocytic components (PkCSP and PkSSP2) we
hoped to understand the role of the different antigens in
protection. Endpoints for all three experiments were parasitemia
after sporozoite challenge and in vitro T cell and antibody
responses. We begin by presenting each experiment separately,
including parasitemias after challenge and immune responses. At
the end of the paper, we combine results from all three studies to
look at the correlation of immune responses with protection.
METHODS
Animals
Rhesus monkeys (Macaca mulatta) descended from Indian stock were
used for all three experiments. Animals were from 6 to 16 years old
andofbothsexes.ForExperiment#1,monkeyswereobtainedbyand
housed at Southern Research Institute, Frederick MD. For Experi-
ments #2a n d#3, monkeys were obtained by and housed at the
Walter Reed Army Institute of Research/Naval Medical Research
Center Silver Spring,MD. Experiment #1 was approvedbythe SRI
Institutional Animal CareandUse Committee. Experiments#2a n d
#3 were approved by the WRAIR/NMRC Institutional Animal
CareandUseCommittee.Allexperimentswereconductedaccording
to Guide for the Care and Use of Laboratory Animals 1996.
Animals were selected to be in general good health, and to have
no history of prior exposure to malaria or pox viruses. Prior to
selection for the studies serum specimens from all animals were
tested in IFAT assays against Pk sporozoites and Pk infected red
cells, and all animals with positive serum titers at dilutions of 1:80
or higher were excluded.
Plasmid vaccines
The DNA plasmid vaccines encoding Pk genes have been previously
described [45]. Briefly, DNA sequences encoding the full length
genes from the Pk H strain of PkCSP, PkSSP2, and PkAMA-1 and
the 42 kD C terminal fragment of PkMSP-1 were cloned into the
VR1020 mammalian expression vector (Vical Inc, San Diego CA).
This vector contains a CMV promoter, and a TPA signal sequence.
Each gene was cloned into a separate plasmid. DNA plasmids for
vaccination were produced by Vical, Inc and contained less that 0.6
EU of endotoxin per mg and were at least 80% super-coiled.
Plasmids were diluted in PBS pH 7.2 prior to injection.
PLG formulation of DNA plasmids. In Experiment #1s o m e
animalswereimmunized with DNAplasmids adsorbedto poly-lactic
co-glycolide (PLG) particles. Formulation of these DNA-PLG
particles was as previously described [50]. Each of the 4 DNA
plasmids was adsorbed to separate PLG particles. A dose equivalent
to 0.5 mg of each plasmid was injected in a total volume of 1ml.
Poxvirus
The poxvirus vaccines encoding Pk genes have been previously
described [45]. Briefly, the same four Pk DNA sequences which
were used to construct the Pk DNA plasmids were cloned into the
COPAK poxvirus immunization vector (Virogenetics, Troy, N.Y).
COPAK is derived from the Copenhagen strain of vaccinia virus.
Each Pk gene was cloned into a separate COPAK virus.
Immunizations
DNA injections
Experiments #1 and #3. DNA was diluted in PBS pH 7.2 and
immunizations were given with a #20 gauge needle and syringe.
PLG formulated DNA was injected using a #18 gauge needle
because of increased viscosity. Each injection had a total volume of
1 ml and a total of 0.5 mg of plasmid. Each plasmid was injected
separately and subsequent injections of each plasmid were into the
same muscle: PkCSP right rectus femoris, PkSSP2 left rectus
femoris, PkAMA1 right triceps, and PkMSP1 left triceps.
Experiment #2. Immunizations in this experiment were the
same as in Experiments #1 except for the group receiving 5 mg of
PkCSP DNA per injection. Because of increased viscosity, for this
group the DNA was diluted in 2 ml of PBS, and 1 ml was injected
into each femoral muscle.
COPAK injections were given im with a #20 gauge needle and
syringe into the right rectus femoris muscle in 1 ml of PBS pH 7.2.
All COPAK vaccinations used 2610
8 pfu of virus for each malaria
antigen. For multiple antigen COPAK immunizations, all vaccines
were mixed together in the same syringe in 1 ml of PBS and
delivered into the same site, a total of 8610
8 pfu . Control COPAK
for the Pk4 vaccine was 8610
8 pfu of parental COPAK virus.
Malaria Parasites
Plasmodium knowlesi H strain sporozoites were grown in Anopheles
dirus mosquitoes. Sporozoites were harvested 14 days after
mosquitoes had fed on an rhesus monkey infected with Pk.
Harvesting was by the Ozaki method. Sporozoites were diluted in
E199 medium with 5% normal rhesus serum and counted with
a hemocytometer. 100 sporozoites in a total volume of 1 ml were
injected IV on the day of challenge.
Beginning 6 days after sporozoite challenge, each day at 1 PM
blood was taken by ear prick and prepared for thin and thick
malaria smears using Giemsa stain at pH 7.01. For thin smears,
20,000 red cells were examined. For thick smears, 0.025 mlo f
blood were examined. These data was used to calculate the
percent infected red blood cells. Animals were followed for 30 days
after challenge. To minimize morbidity, monkeys were treated
when their parasitemia exceeded 1% in experiment #1. Because
of the lack of morbidity in experiment #1 the treatment threshold
was raised to 2% in experiments #2 and #3. Monkeys were also
treated if their hematocrit fell to 50% of baseline values, which
occurred in several animals with malaria infections which persisted
at low levels for longer than 18 days after sporozoite challenge.
Measurement of malaria antibodies
Plasma was tested by ELISA for IgG titer using as capture antigens
each of the four Pk antigens used in the immunization studies.
Capture antigen for PkCSP was an E. coli produced full length
protein used at 0.1 microgram per ml provided by Sanjay Kumar.
Capture antigen for the full length PkSSP2, PkAMA-1, and the
PkMSP-1 42kD fragment we produced by in vitro synthesis using
the Rapid Translation System RTS 500 E. coli HY kit (Roche
Diagnostics Corporation, Indianapolis, IN). These capture anti-
gens were used at concentrations of 1 to 4 micrograms per ml in
PBS pH 7.2 in Immulon II 96 well plates (Dynex Technologies
Inc., Chantilly, Virginia ). Plates were blocked with 5% milk
powder in PBS for 2 hours. Plasma samples were diluted in 3%
non-fat dry milk in PBS and kept at room temperature for 4–
DNA/Poxvirus Malaria Vaccine
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kegard Perry Laboratories, Gaithersburg MD) at a 1:10,000
dilution in 3% non-fat dry milk was added for 1 hour, and
substrate was ABTS (Kierkegard Perry Laboratories). OD was
read using a SPECTRA MAX 190 ELISA reader (Molecular
Devices Corp., Sunnyvale, CA). Endpoint titer for each sample
was the highest plasma dilution at which the OD was greater than
twice the value of plasma from naı ¨ve monkeys.
Measurement of T cell responses
ELIspot assay for cells producing INF-c was done as previously
described [51]. Briefly, MAIP S 4510 plates (Millipore, Bedford,
MA) were coated with BMS 107, a monoclonal antibody against
human interferon c, (Bender Med Systems, Austria) at 5 mg/ml in
PBS. 2610
5 cryopreserved PBMC were added per well in a total
volume of 0.2 ml containing medium alone, concanavalin A at 10
microgram per ml or malaria antigen. After overnight incubation,
a secondary anti-human biotinylated anti-IFN-c antibody, clone
7B6-1 (Mabtech, Cincinnati, OH) was added at concentration of
2.5 mg/ml. Spots were developed using streptavidin -alkaline
phosphatase conjugate (PharMingen, San Diego, CA) at 1:2000
dilution at room temperature for 1 hr. Following six washes with
PBS Tween, spots were developed with 5-bromo-4 chloro-3
indolyl phosphatase (BCIP) (Sigma-Aldrich, St. Louis, MO). Spots
were read using a CTL ELIspot reader (Cellular Technology Ltd.,
Cleveland,OH). A response was considered positive only if there
were greater than 50 spots per million cells, and if responses were
greater than twice those recorded in the media controls.
Technicians were blinded as to the vaccination group of the
animals whose cells they were testing.
Malaria test antigens for ELIspot
In all three studies we tested ELIspot response to the PkCSP antigen
using pools of synthetic 20 aa peptides overlapping by 10 aa and
spanning the antigen. The concentration of each peptide in the pool
was 10 mM. In experiment #1, response to PkMSP1 was tested
using an E. coli derived PkMSP1 19kD fragment tested at 2 mM( a
gift of Dr. Sanjai Kumar). This 19kD fragment is contained within
the 42kD PkMSP1 fragment used in our Pk vaccines. In experiment
#3, we tested response to the PkAMA-1 antigen using pools of
synthetic 15 aa peptides overlapping by 11 aa and spanning the
antigen. The concentration of each peptide in the pool was 2 mM.
Statistical Methods: For each of the three separate experiments,
we used Student’s T test and Fisher’s Exact Test for analysis of
continuous and dichotomous variables respectively. For analysis of
combined data from the three experiments in the final figure, we
used a simple linear regression model.
RESULTS
Experiment # 1. Our goal in experiment #1 was to compare
three priming regimens: 3 injections of DNA in PBS, 1 injection of
DNA in PBS, and 3 injections of DNA formulated on PLG
microspheres. All three groups received a boost with the same
COPAK virus vaccine 16 weeks after the last DNA immunization.
A control group received a mock vaccine, with control plasmid on
PLG microspheres and a boost with control COPAK virus
(Table 1). The three experimental groups were immunized with
DNA encoding four Pk antigens, PkCSP, PkSSP2, PkAMA-1, and
PkMSP1. Each of these four DNA plasmids was given into
a separate im site (the left and right triceps and the left and right
quadriceps) to preclude any interactions at the injection sites. Four
weeks after the COPAK dose, all animals were challenged with
100 Pk sporozoites given iv and followed for the development of
blood stage parasitemias. Blood was taken for in vitro studies
before the first injection, four weeks after each DNA vaccination,
and prior to challenge.
Figure 1 shows the parasitemias for individual monkeys plotted
by vaccine group. We followed each animal until its parasitemia
exceeded 1% at which time it was treated with anti-malarial drugs.
Three animals, two in the control group and one in the PLG DNA
group were inadvertently treated for malaria at parasitemias lower
than 1% (these are shown with open markers). Figure 1 panel E
shows the geometric mean parasitemia for each vaccine group for
each day that at least three animals remained untreated for
malaria. Table 2 summarizes the information on the first day
parasites appeared in the blood and the day they reached 1%.
The DNA priming method strongly affected the efficacy of the
DNA/COPAK vaccine. The group of monkeys primed with three
doses of DNA in PBS were best protected (p,0.05 Fisher Exact
test, Table 2). Of the 5 animals primed with three doses of DNA in
PBS one monkey never developed blood stage parasites pre-
sumably due to complete inhibition of malaria in the sporozoite
and liver stages. The other 4 animals developed parasitemias at the
same time as the Control animals but as a group had lower
geometric mean parasitemia on all days, although this did not
reach statistical significance (Figure 1 panel E). Growth of parasites
was similar in all groups up until days 12–13 when growth slowed
in 3 of 4 infected animals in the DNA Pk463/COPAK group.
These 3 animals controlled their blood stage infections below 1%
parasitemia without drug therapy. In contrast, all 5 monkeys
receiving only a single dose of DNA in PBS developed parasitemia,
and 4 of 5 reached parasite levels over 1% and were treated. All 5
monkeys receiving 3 doses of DNA on PLG microspheres all
became infected, and the 4 animals followed to the end of the
study developed parasitemias over 1%.
Table 1. Immunization schedule for Experiment #1
..................................................................................................................................................
Group Vaccine Name Dose 1 Dose 2 Dose 3 Dose 4 Challenge
wk 0 4 8 24 28
1 DNA Pk463/COPAK DNA DNA DNA COPAK X
2 DNA Pk461/COPAK DNA COPAK X
3 PLG Pk463/COPAK DNA on PLG DNA on PLG DNA on PLG COPAK X
4 Control Control DNA on PLG Control DNA on PLG Control DNA on PLG Control COPAK X
Five monkeys in each of four vaccine groups were immunized and challenged with Pk malaria sporozoites. ‘Pk4’ refers to four Pk antigens (PkCSP, PkSSP2, PkAMA1, and
PkMSP1). ‘DNA’ indicates plasmid vaccines in PBS. ‘PLG’ indicates plasmid vaccines complexed to PLG particles. ‘COPAK’ indicates vaccinia encoding malaria antigen.
Animals in the Control group received a mock vaccine consisting of plasmid without malaria inserts complexed to PLG particles followed by parental COPAK without
malaria inserts. (See text for more details).
doi:10.1371/journal.pone.0001063.t001
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PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1063Figure 2. summarizes the immune responses for individual
monkeys in experiment #1. Both ELISA’s and INF-g ELIspot
assays were run on frozen samples taken before immunization, four
weeks after the final DNA immunization, on the day of COPAK
boost,andfourweeksafterboostatthetimeofmalariachallenge.No
significant antibody or IFN-g responses were seen at baseline or after
the priming immunizations (data not shown). After COPAK boost,
substantial T cell and antibody responses appeared.
Figure 2 panel A plots the interferon-c ELIspot responses after
COPAK boost for the two antigens tested, PkCSP and PkMSP1.
The group primed with DNA on PLG microspheres had the
highest average ELIspot responses for both antigens however this
was not statistically significant (p=0.58 Student’s T test) because
of the large variation in responses between animals.
Figure 2 panel B shows antibody responses to each of the four
vaccine components after the COPAK boost. The group of
animals primed with three doses of DNA in PBS had the highest
geometric mean titers of serum IgG for all four antigens. For most
antigens, these differences were statistically significant (see legend).
Experiment #2 was designed to answer two questions. Firstly,
can the PkCSP vaccine alone or with the PkSSP2 vaccine protect
as well as the four antigens Pk4 vaccine (with PkCSP, PkSSP2,
PkAMA-1, and PkMSP1)? Secondly, does increasing PkCSP DNA
doses during priming from 0.5 mg to 5.0 mg lead to stronger
Figure 1. Panels A–D show the % parasitemia for individual monkeys by vaccine group according to the day after sporozoite challenge for
Experiment #1. Data shows the first day parasites were detected and continues until the animal was drug treated when parasitemia exceeded 1% (
3 animals inadvertently treated at lower parasitemias have open symbols). For comparison, in each panel the grey line shows the mean parasitemia
for the Control group. In panel C, one animal never became parasitemic as indicated by x-x. Panel E shows the geometric mean parasitemias for
vaccine groups for all days in which at least three animals had not been drug treated. (The monkey from the DNA Pk463/COPAK group which did not
become infected was excluded from the average).
doi:10.1371/journal.pone.0001063.g001
DNA/Poxvirus Malaria Vaccine
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Table 3 gives the immunization schedule for experiment #2. As in
experiment #1, each component of the DNA vaccine was given
im by a single 1 ml injection into a separate limb. The one
exception was the group receiving 5 mg of PkCSP DNA, which
received two injections of 1 ml into each thigh because of concerns
about concentration and viscosity of the DNA vaccine. In
experiment #2 monkeys were followed until parasitemias
exceeded 2% and then treated with anti-malarial drugs.
Experiment #2. Vaccine effects on parasitemia.
Figure 3 panels A–E show the parasitemias for individual
monkeys in this experiment while panel F shows the geometric
mean parasitemias for each group. Table 4 summarizes in-
formation on the day parasites were first detected following
challenge, and the day when each animal’s parasitemia exceeded
2%. Figure 3 panel A shows parasitemias in Control monkeys
immunized with the mock vaccine. All Control animals had
parasites detected in the blood on day 7 or 8 after sporozoite
challenge, showed logarithmic parasite growth, and all were
treated on day 11 after they exceed 2% parasitemia. Panel E shows
parasitemias for the monkeys receiving the Pk4 DNA63/COPAK
vaccine (given identically as in Experiment #1). In Experiment
#2, no monkeys were sterilely protected however the vaccine had
a substantial impact on infection. There was a statistically
significant one day delay in the appearance of the first parasites
compared to Control (p=0.03, Fisher Exact test). Geometric
mean parasitemias were lower in the Pk4 DNA63/COPAK
vaccine group with statistically significant differences from Control
monkeys on days 8, 10, and 11 (p,0.05, Student’s T test). Parasite
numbers increased at similar rates in all groups until day 11, when
4 of 5 of the monkeys receiving the Pk4 DNA/COPAK vaccine
showed a slowing of parasite growth. As a result, 2 of 5 monkeys in
this vaccine group never reached 2% parasitemia, and 2 animals
had a delay of several days until treatment was required,
a statistically significant difference from Control animals
(p,0.001, Fisher Exact test).
Figure 3 panels B, C, and D and Table 4 show parasitemias for
animals receiving the PkCSP vaccine alone, the high DNA dose
PkCSP vaccine, and both the PkCSP and PkSSP2 vaccines.
Monkeys receiving the PkCSP 0.5 mg DNA/COPAK vaccine
showed a one day delay in the time to first parasitemia as
compared to the control group (p=0.03, Fisher Exact test).
Animals receiving the ten-fold higher doses of the DNA vaccine
did not show any increased time to first parasitemia compared to
monkeys given lower doses. Curiously, monkeys receiving
concurrent vaccinations with both the PkCSP and the PkSSP2
antigens were less protected than animals receiving the PkCSP
vaccine alone (p=0.03, Fisher Exact test), showing first parasites
in the blood the same day as the Control group.
Ofthe15animalsreceivingonlythepre-erythrocyticPkCSPand/
or PkSSP2 vaccines, none was able to control its blood stage parasite
growth and all needed treatment for parasitemias over 2% by day
13. This contrasts with the monkeys receiving the 4 antigen vaccine
which included PkAMA1 and PkMSP1 (p,0.001 Fisher’s Exact
Test). Of these 5 monkeys, 2 animals controlled their parasitemia
without drug treatment, 2 had long delay until parasitemia reached
treatment levels, while one was treated on day 11.
Figure 4. shows immune responses of animals to the PkCSP
antigen in Experiment #2. Interferon-c ELIspot T cell responses
to PkCSP were measured in all animals at baseline, four weeks
after the third DNA injection, and two weeks after the COPAK
boost. After three DNA immunizations only weak T cell responses
were detected (Figure 4 panel A). Animals receiving three 5.0 mg
doses of PkCSP plasmid had slightly higher numbers of INF-c
producing T cells than did animals receiving 0.5 mg doses
(p=0.11). Monkeys receiving 0.5 mg doses of both the PkCSP
and PkSSP2 DNA vaccines given in opposite legs (mean 16 spots/
million sd=11) had lower levels of PkCSP specific interferon-c
responses than monkeys receiving 0.5 mg PkCSP DNA alone
(mean 54 spots/million sd=36) (p=0.04, Student’s T test).
After boosting with COPAK vaccines, T cell responses to PkCSP
increased in all groups. Monkeys primed with 0.5 mg PkCSP DNA
had the highest T cell response but this was not significantly different
than animals receiving the higher 5.0 mg dose ( p=0.08). Animals
receiving the 2 antigen PkCSP and PkSSP2 vaccine (mean 257
spots/millionsd=271)orthe4antigenPk4DNAvaccine(mean301
spots/million sd=167) had lower interferon-c responses than did
animals receiving the single antigen 0.5 mg PkCSP vaccine (mean
997 spots/million sd=981) (p=0.04, Fishers Exact test).
Figure 4 panel B shows antibodies to PkCSP in experiment #2.
Four weeks after the third DNA immunization, the anti-PkCSP
titers were highest in the monkeys receiving the 5.0 mg plasmid
dose (p,0.05) although titers were still modest. After the COPAK
boost, all vaccine groups had high antibody titers to PkCSP.
Although monkeys primed with the 5 mg DNA had the highest
titers after boost, this was not statistically different from monkeys
primed with 0.5 mg DNA (p=0.28). Antibodies to PkCSP were
the same in groups receiving 0.5 mg of PkCSP DNA alone, or
simultaneous vaccination with 0.5 mg of PkSSP2 DNA.
Very large PkCSP DNA doses gave higher immune T cell and
antibody responses after DNA vaccination. However, these
Table 2. Summary of Parasitemia Data in Experiment #1
......................................................................
Vaccine
Day 1
st
parasitemia
Mean day 1
st
parasitemia
Day .1%
parasitemia
Mean Day
.1%
parasitemia
DNA Pk461/COPAK 8 13
81 3
9 8.8 13 13+
91 3
10 never
DNA Pk463/COPAK 8 never
8 never
10 9.0+ never 14+ *
10 14
never -
PLG Pk463/COPAK 7 12
81 2
8 8.2 12 12.25
81 3
10 unknown
Control 8 unknown
81 4
9 9.0 unknown 13
91 2
11 13
‘Day 1
st parasitemia’ is the day after sporozoite challenge when parasites were
first seen on malaria smear. ‘Day .1% parasitemia’ is the day of drug treatment
(‘unknown’ means that monkeys were drug treated before reaching 1%
parasitemia). Priming with 3 doses of DNA in PBS gave better protection than
priming with 1 dose of DNA in PBS or 3 doses of DNA on PLG (*p=0.04 Fisher’s
Exact test).
doi:10.1371/journal.pone.0001063.t002
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PLoS ONE | www.plosone.org 5 October 2007 | Issue 10 | e1063Figure 2. Panel A. Interferon-c ELIspot was tested for only two antigens: PkCSP and PkMSP1. Spots in medium controls were subtracted from
antigen test wells, and the results averaged. Priming with DNA on PLG gave a stronger interferon-c response than DNA in PBS but this was not
significant (p=0.58). Panel B. Geometric mean antibody titers by ELISA at time of sporozoite challenge for each of the four malaria vaccine antigens.
Priming with 3 doses of DNA gave higher antibody levels than did a single DNA priming dose for PkCSP, PkMSP1 and PkAMA1 antigens (p,0.05).
Priming with 3 doses of DNA in PBS produced higher serum antibody titers than did priming with 3 doses of DNA on PLG for PkCSP, PkSSP2, and
PkAMA1 antigens (p,0.05).
doi:10.1371/journal.pone.0001063.g002
Table 3. Immunization schedule for Experiment #2
..................................................................................................................................................
Group Vaccine Name DNA amount Dose 1 Dose 2 Dose 3 Dose 4 Challenge
wk 0 4 8 24 28
1 DNA Pk463/COPAK 0.5 mg of 4 DNAs DNA DNA DNA Pk4 COPAK X
2 PkCSP 0.5 mg/COPAK 0.5 mg DNA DNA DNA PkCSP COPAK X
3 PkCSP 5.0 mg/COPAK 5.0 mg DNA DNA DNA PkCSP COPAK X
4 PkCSP+PkSSP2/COPAK 0.5 mg of 2 DNAs DNA DNA DNA PkCSP+PkSSP2 COPAK X
5 Control 2.0 mg DNA DNA DNA Control COPAK X
Five monkeys in each of five vaccine groups were immunized and challenged with Pk malaria sporozoites. The four antigen vaccine given Group 1 was identical to that
given to Group 1 in Experiment 1. Group 2 received only the PkCSP components of the vaccine given to Group 1. Group 3 received a ten-fold larger dose of the PkCSP
DNA than Group 2 and the same dose of PkCSP COPAK. Group 4 received only the PkCSP and PkSSP2 components of the vaccine given to Group 1. Group 5, the Control
group, received a mock vaccine consisting of plasmid DNA without malaria antigen inserts followed by parental COPAK without malaria inserts. (See text for more
details).
doi:10.1371/journal.pone.0001063.t003
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PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e1063improved responses after DNA priming did not translate into
improved immune response after the PkCSP COPAK boosting.
Neither did the animals receiving high dose DNA priming show
any improved protection against malaria as compared with those
receiving low dose priming.
Simultaneous vaccination with PkSSP2 DNA into a separate limb
seems to have inhibited interferon-c T cell responses to PkCSP
DNA. This is seen in a lower PkCSP specific interferon-c response
after the third DNA dose, as well as after the COPAK boost. These
lowerresponsesweremirrored inacomplete lackofprotectioninthe
Figure 3. Panels A–E show the % parasitemia for individual monkeys by vaccine group according to the day after sporozoite challenge for
Experiment #2. Data shows the first day parasites were detected and continues until the animal was treated with anti-malarial drugs. For
comparison, in each panel the grey line shows the mean parasitemia for the Control group. Panel F shows the geometric mean parasitemias for all
the vaccine groups for all days in which at least three animals had not been drug treated.
doi:10.1371/journal.pone.0001063.g003
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PLoS ONE | www.plosone.org 7 October 2007 | Issue 10 | e1063PkCSP+PkSSP2 group. We had hoped that using two pre-
erythrocytic antigens would improve protection, but it appears that
a negativeinteractionisoccurringwhen animalsareexposedtothese
two antigens. Interestingly, this interaction affected interferon-c
responses but did not affect antibody responses to PkCSP.
Finally, only animals receiving the four antigen vaccine
including the blood stage antigens PkMSP1 and PkAMA-1 were
able to control their malaria infections once organisms appeared in
the blood. This is strong evidence that this blood stage protection
is due to the antigen specific responses to these two proteins
induced by genetic vaccination. In the absence of a group
receiving only the PkMSP1 and PkAMA1 vaccines, we do know if
the two pre-erythrocytic stage antigens contribute to this blood
stage efficacy, or if protection against blood stage infections would
be seen with a vaccine containing only PkMSP1 and PkAMA1.
Experiment #3. In this experiment, we compared 7 week and
21 week intervals between the third DNA dose and COPAK boost
using the Pk463DNA/COPAK vaccine. (A 16 week interval was
used in Experiments #1 and #2. It was our intention to compare
7 and 16 week intervals in this experiment, however logistical
problems caused a delay). The vaccination and challenge were as
in Experiments #1 and #2. There were 4 animals in the 7 week
interval group, and 5 animals in the other two groups.
Figure 5 panels A–C show the parasitemias for individual
monkeys in Experiment #3 and panel D shows the geometric
mean parasitemias for each group. All Control and vaccinated
monkeys developed blood stage infections on days 7–9 after
sporozoite injection. Neither of the vaccine groups had a delay to
day of first parasitemia compared to the Control group. However,
compared to the Control and 7 week interval groups, the Pk4
DNA63/COPAK 21 week group had a lower mean parasitemia
on days 8–11 (p,0.05 by Student’s T test) and a one day delay to
day .2% parasitemia compared to the Control group (p=0.023
Fishers Exact test). All monkeys required drug treatment and there
were no self-cures. Immune responses at the time of challenge
showed no statistically significant differences between the groups
with 7 or 21 week intervals in antibody titers by ELISA or in
interferon-c ELIspots, although there were slightly higher T cell
responses in the group with the longer interval (data not shown).
Conclusions from Experiment 3. Comparing the groups with 7
and 21 week intervals, the longer interval resulted in lower mean
daily parasitemias and a delay in reaching 2% parasitemia.
Although the group with 21 week intervals was not as well
protected as were the groups with 16 week intervals in Experi-
ments #1 and #2, we are loath to conclude that one is interval is
superior as the animals in the three experiments were challenged
at different times with different batches of sporozoites.
Correlation of Immune Responses to PkCSP with parasitemia
in experiments 1, 2, and 3.
The small numbers of animals in each of the three experiments
lead us to combine the results for correlation of immune response
at the time of sporozoite challenge and protection against malaria.
There was no correlation between antibody titers to any vaccine
antigen with day of first parasitemia or day when the treatment
threshold of parasitemia was reached (data not shown). Interferon-
c ELIspot responses for PkMSP1 and PkAMA1 were only tested in
single experiments and the small samples size provides insufficient
statistical power to attempt correlations with protection. However,
interferon-c ELIspot responses to PkCSP were measured for all
animals in these three experiments and they showed a negative
correlation with the appearance of first parasites in the blood.
Figure 6 shows this surprising result. We have included all
animals from Experiments 1, 2, and 3 that were immunized with
any vaccine containing PkCSP (i.e. Control animals are excluded).
In panel A, we have plotted the PkCSP antibody titer on day of
challenge vs. day of first parasitemia. There is no correlation
between antibody titer and time to parasitemia. Figure 6. panel B
shows a plot of interferon-c ELIspot to the PkCSP antigen for the
same animals. Here there is a statistically significant negative
association, with animals having stronger responses showing
parasites earlier in the blood (p=0.04, linear regression model).
This negative correlation of PkCSP interferon-c response and time
to first parasite detected is also true for each of the three
experiments analyzed individually, although the smaller numbers
do not lead to statistically significant results (data not shown).
DISCUSSION
Our goal in developing a primate malaria vaccine model is to
define the important parameters governing vaccine efficacy prior
to designing malaria vaccines studies in humans. We draw four
lessons from the malaria vaccine experiments presented in this
Table 4. Summary of parasitemia data in Experiment #2
......................................................................
Vaccine
Day 1
st
parasite
Mean day 1
st
parasite
Day .2%
parasitemia
Mean Day .2%
parasitemia
PkCSP 0.5 mg63/
COPAK
81 1
81 1
88 . 4 * 12 11.6
81 2
10 12
PkCSP 5.0 mg63/
COPAK
71 1
81 1
8 8.0 12 11.8
81 2
91 3
PkCSP+PkSSP263/
COPAK
71 1
71 1
7 7.4 11 11.4
81 2
81 2
DNA Pk463/COPAK 8 11
81 5
88 . 4 * 16 14+**
9 never
9 never
Control 7 11
71 1
7 7.4 11 11
81 1
81 1
‘Day 1
st parasite’ is the day after sporozite challenge when a parasite was first
seen on malaria smear. ‘Day .2% parasitemia’ is the time of drug treatment.
The group receiving the four antigen vaccine and the single antigen PkCSP
vaccine had a delay in the appearance of parasites in the blood (*p=0.03 vs
Control group, Fisher’s Exact Test). The group receiving high doses of PkCSP
DNA priming was not as well protected. Co-immunization with PkSSP2 and
PkCSP was worse than immunization with PkCSP alone (p=0.03). Only the
monkeys receiving all 4 antigens were protected against high parasitemias
(**p,0.001 vs Control group).
doi:10.1371/journal.pone.0001063.t004
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PLoS ONE | www.plosone.org 8 October 2007 | Issue 10 | e1063paper: 1) The timing, number and formulation of the DNA
injections is critical to the protective efficacy of the DNA/COPAK
vaccine, 2) DNA/COPAK malaria vaccines can provide pro-
tection against both pre-erythrocytic and blood stage malaria
infection, 3) the antigens can interfere with each other in a multi-
antigen vaccine even when they are given at separate injection
sites, and 4) we have not yet identified the immune responses
which protect these immunized monkeys against malaria.
1) In this prime/boost vaccine model in rhesus monkeys, the dose,
number, and formulation of DNA injections are critical for vaccine
efficacy. However, the absolute quantity of DNA injected in priming
beforeCOPAKboostwaslessimportant.Inexperiment#1,the Pk4
DNA63/COPAK vaccine with 3 monthly DNA doses provided
amoderatelevelofprotectionagainstsporozoitechallenge,similarto
whatwe havepreviouslyreported[45,46]. Primingwith onlya single
dose of DNA plasmid led to similar interferon-c responses, but
reduced antibody levels and less vaccine efficacy. Formulating the
three DNA doses on PLG microspheres enhanced the interferon-c
responses to the vaccine but also reduced antibody responses and
efficacy. In Experiment #2, large doses of PkCSP plasmid gave
higher immune responses before the viral boost, but this did not
translate into better immune responses or protection after boost. In
Experiment#3,shorterintervalsbetweenprimeandboostledtoless
protection. The lesson for human vaccine development would seem
to be that much effort should be spent in optimizing priming
regimens in human DNA prime/viral boost trials, with emphasis on
finding optimum intervals [52] and formulations rather than
escalating DNA quantities.
2) In these experiments, only animals receiving the four antigen
vaccines were able to control parasite growth after parasites were
detected in the blood. Of the four malaria antigens in this vaccine,
PkCSP and PkSSP2 are primarily expressed on sporozoites [53–
57] and may be present in early stage infected liver cells. PkAMA1
and PkMSP1 are expressed in infected red cells and late stage
infected liver cells [58] , although there is some data indicating
that AMA1 is also expressed in sporozoites [54,59]. Animals
receiving vaccines with the PkCSP and or PkSSP2 antigens
demonstrated a delay in appearance of parasites in the blood,
consistent with killing of sporozoites or infected liver cells and
development of fewer liver schizonts [60]. However, in animals
Figure 4. Panel A shows interferon-c ELIspot response to PkCSP by vaccine group prior to vaccination, after the third DNA vaccination, and after
the COPAK boost. After the third DNA vaccination, the PkCSP 5.0 mg group has the highest response but this is not significantly greater than the
PkCSP 0.5 mg group (p=0.11). After the third DNA vaccination monkeys receiving both PkCSP and PkSSP2 immunizations had significantly lower
responses to PkCSP than did animals receiving only PkCSP DNA (p=0.04). After the COPAK boost, monkeys primed with low dose PkCSP 0.5 mg DNA
had the highest response interferon-c response (p=0.08 vs high dose PkCSP, p=0.04 vs Pk4 vaccine, p=0.04 vs PkCSP+PkSSP2). Panel B shows IgG
responses at the three time points. After three DNA vaccinations, serum titers were highest in the high dose DNA PkCSP 5.0 mg group (p=0.01). After
boosting with recombinant COPAK virus, monkeys primed with the high dose DNA had the highest serum IgG titers but this was not significantly
different from the other vaccine groups.
doi:10.1371/journal.pone.0001063.g004
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PLoS ONE | www.plosone.org 9 October 2007 | Issue 10 | e1063which only received vaccines with PkCSP or PkSSP2, once red
cells became infected there were logarithmic increases of parasites.
Only animals receiving vaccines containing the PkAMA1 and
PkMSP1 antigens could control their red cell infections below
levels requiring drug treatment. This is strong evidence that the
immune response to these blood stage antigens induced by
a DNA/viral vaccine was effective in limiting parasite growth.
Most work on blood stage vaccines, including AMA1 and
MSP1, has focused on protein vaccines where the correct folding
and glycosylation of antigens has been critical for the development
of inhibitory antibodies and protection [11–23]. Both the DNA
plasmid and viral components of our vaccine are based on parasite
DNA sequences which the mammalian cell uses to produce
antigenic proteins using its intrinsic controls for folding, post-
translational modifications, and degradation. These vaccine
antigens may or may not have the same folding and glycosylation
as they have in the parasite. We believe that the lesson for human
vaccine development is that blood stage antigens can be protective
in genetic vaccines, and should be included despite the limited
ability to control their final three dimensional structures. It is not
clear that the protective effect of these genetic blood stage vaccines
is due to the direct induction of inhibitory antibodies. The typical
course of parasitemia in our vaccinated animals is a logarithmic
rise in blood stage parasites for several days which then slows,
plateaus, and decreases. This is not the pattern expected from
a vaccine which induces high levels of protective antibody, where
Figure 5. Panels A–C show the % parasitemias for individual monkeys by vaccine group according to the day after sporozoite challenge for
Experiment #3. Data shows the first day parasites were detected and continues until the animal was treated with anti-malaria drugs. For
comparison, in each panel the grey line shows the mean parasitemia for the Control group. Panel D shows the geometric mean parasitemias for all
the vaccine groups for all days in which at least three animals had not been drug treated. For each day 8–11 the mean parasitemia for the group
receiving the booster dose at the 21 week interval was lower than the other groups (p,0.05, Student’s T test).
doi:10.1371/journal.pone.0001063.g005
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PLoS ONE | www.plosone.org 10 October 2007 | Issue 10 | e1063one might expect a uniform slow rate of parasite growth. An
alternative hypothesis is that the genetic vaccines have induced
helper T cell responses to the blood stage antigens, which allows
the host to rapidly produce inhibitory antibodies after antigens
appear in the blood. We are currently examining this hypothesis
by comparing the inhibitory effects of serum antibody in
immunized animals both before and after challenge.
3) Experiment #2 provided evidence of antigen interference
between PkCSP and PkSSP2. Our unexpected finding is that
administration of the PkSSP2DNA vaccine intheleftleg diminished
the interferon-c T cell responses and efficacy of the PkCSP DNA
vaccine given in the right leg. However, antibody responses to
PkCSP DNA vaccination were not affected. Monkeys in the four
antigenvaccinegroup,whichreceivedthePkCSPandPkSSP2DNA
Figure 6. Immune response to PkCSP antigen at time of challenge for individual animals by day to first parasite seen in blood. Data from
Experiments #1, 2, and 3 are plotted. Data from Control animals are not included. Panel A shows PkCSP endpoint ELISA titers where there is no
significant correlation. Panel B shows PkCSP interferon-c ELIspot titers with a linear regression line included. There is a significant negative correlation
(p=0.04), animals with lower ELIspot responses having longer times to the appearance of first parasite in the blood.
doi:10.1371/journal.pone.0001063.g006
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PLoS ONE | www.plosone.org 11 October 2007 | Issue 10 | e1063vaccines in the legs but also received the PkAMA1 and PkMSP1
DNA vaccines in the arms, also had lower interferon-c responses to
PkCSP thanthe groupreceivingPkCSP alone.Wedo notpretend to
understand these phenomena. Previously, inhibition between DNA
vaccines has been described when the vaccines were given together
in the same syringe, and was thought to be due to competition
between plasmids within mammalian cells [61–63]. To avoid such
competition, we administered each of our DNA vaccine antigens
into muscles on different limbs. However, this is not the first instance
of undesirable interactions between CSP and SSP2 vaccines [64]. If
the PkSSP2 antigen is detrimental, it might be interesting to test
a trivalent vaccine with PkCSP, PkMSP1, and PkAMA1. Similarly,
it will be important to test for inhibition in multi-antigen human
malaria vaccines.
4) The most surprising result of our experiments is the negative
correlation between interferon-c responses to the PkCSP and time to
first parasite detected in the blood. Why should stronger T cell
responses lead to parasites appearing sooner? We believe that T cell
responses are protective but that the protective T cell responses are
in some way reciprocal to the T cell responses we are measuring.
Our assaymeasures interferon- c using circulating lymphocytesinan
overnight stimulation assay. This assay primarily measures responses
from CD4
+ T cells which are activated effector cells [51]. In humans
immunized with pre-erythrocytic vaccine antigens, overnight ELI-
spot assays which measure circulating active effector cells correlate
poorly with protection, but multi-day cultures which measure
effector memory cells have a stronger association with protection
from malaria challenge [65]. It is likely that the true cells which are
killing parasites are immune T cells residing in the liver, which are
difficult to sample [66]. Perhaps the puzzling inverse correlation we
havedescribedisbecausethenumberofantigenspecificeffectorcells
remaining in the circulation is inversely related to the numbers of
protective immune cells which have homed to the liver. We are
developing methods for directly measuring immune responses in
monkey liver so that we can test this hypothesis in future
experiments. The implication of this finding for human vaccine
studies is that we have not found an immune correlate of protection.
Until we do, pre-erythrocytic vaccines should not be optimized to
produce specific immune responses but instead protection against
sporozoite challenge must continue to be the standard.
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